Clever Leaves (CLVR) versus Its Peers Financial Contrast

Clever Leaves (NASDAQ:CLVRGet Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Clever Leaves to similar businesses based on the strength of its valuation, profitability, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Clever Leaves and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clever Leaves -297.42% -43.15% -24.69%
Clever Leaves Competitors -4,343.45% -115.55% -11.42%

Analyst Recommendations

This is a summary of current ratings for Clever Leaves and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clever Leaves 0 1 2 0 2.67
Clever Leaves Competitors 6120 20668 43013 857 2.55

Clever Leaves currently has a consensus target price of $6.00, suggesting a potential upside of 277.36%. As a group, “Pharmaceutical preparations” companies have a potential upside of 110.79%. Given Clever Leaves’ stronger consensus rating and higher probable upside, equities analysts plainly believe Clever Leaves is more favorable than its rivals.

Institutional and Insider Ownership

29.0% of Clever Leaves shares are held by institutional investors. Comparatively, 45.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.2% of Clever Leaves shares are held by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Clever Leaves has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Clever Leaves’ rivals have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Clever Leaves and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Clever Leaves $15.37 million -$45.73 million -0.90
Clever Leaves Competitors $1.83 billion $238.18 million -1.65

Clever Leaves’ rivals have higher revenue and earnings than Clever Leaves. Clever Leaves is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Clever Leaves rivals beat Clever Leaves on 7 of the 13 factors compared.

Clever Leaves Company Profile (Get Rating)

Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, and commercialization of cannabinoid products internationally. The Non-Cannabinoid segment is involved in formulating, manufacturing, marketing, selling, distributing, and commercializing homeopathic and other natural remedies, wellness products, detoxification products, nutraceuticals, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.

Receive News & Ratings for Clever Leaves Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clever Leaves and related companies with MarketBeat.com's FREE daily email newsletter.